{"doc_id": "si-2022-0467-reg-1", "parent_doc_id": "si-2022-0467", "section_id": "reg-1", "section_label": "Regulation 1.", "si_number": "S.I. No. 467 of 2022", "title": "and Control of Supply) Regulations 2003 to 2022” includes these Regulations.", "year": 2022, "heading": "1. (1) These Regulations may be cited as the Medicinal Products", "text_raw": "1. (1) These Regulations may be cited as the Medicinal Products \n\n(Prescription and Control of Supply) (Amendment) (No. 5) Regulations 2022. \n\n(2) \n\nThe collective citation “the Medicinal Products (Prescription \nand Control of Supply) Regulations 2003 to 2022” includes these Regulations.", "text_norm": "1 (1) regulation may cited medicinal product (prescription control supply) (amendment) (no 5) regulation 2022 (2) collective citation medicinal product (prescription control supply) regulation 2003 2022 includes regulation", "start_char": 622, "end_char": 913, "source_path": "downloads\\2022\\2022_0466.pdf", "extraction_method": "pdfminer", "checksum": "sha256:6019fd6b368a8c147a0a394bd4c11b96f3897bb771ba4d88d743e1d9a857e78f", "cross_refs": []}
{"doc_id": "si-2022-0467-reg-2", "parent_doc_id": "si-2022-0467", "section_id": "reg-2", "section_label": "Regulation 2.", "si_number": "S.I. No. 467 of 2022", "title": "and Control of Supply) Regulations 2003 to 2022” includes these Regulations.", "year": 2022, "heading": "In these Regulations—", "text_raw": "2. \n\nIn these Regulations— \n\n“Principal Regulations” means the Medicinal Products (Prescription and \nControl of Supply) Regulations 2003 (S.I. No. 540 of 2003); \n\n“Regulations of 2022” means the Medicinal Products (Prescription and Control \nof Supply (Amendment) (No. 4) Regulations 2022 (S.I. No. 402 of 2022).", "text_norm": "2 regulations-- principal regulation mean medicinal product (prescription control supply) regulation 2003 (s.i no 540 2003) regulation 2022 mean medicinal product (prescription control supply (amendment) (no 4) regulation 2022 (s.i no 402 2022)", "start_char": 913, "end_char": 1227, "source_path": "downloads\\2022\\2022_0466.pdf", "extraction_method": "pdfminer", "checksum": "sha256:6019fd6b368a8c147a0a394bd4c11b96f3897bb771ba4d88d743e1d9a857e78f", "cross_refs": []}
{"doc_id": "si-2022-0467-reg-3", "parent_doc_id": "si-2022-0467", "section_id": "reg-3", "section_label": "Regulation 3.", "si_number": "S.I. No. 467 of 2022", "title": "and Control of Supply) Regulations 2003 to 2022” includes these Regulations.", "year": 2022, "heading": "3. The Eighth Schedule (as amended by Regulation 3 of the Regulations", "text_raw": "3. The Eighth Schedule (as amended by Regulation 3 of the Regulations \n\nof 2022) to the Principal Regulations is amended— \n\n(a) by inserting after the entry for “Comirnaty concentrate for \ndispersion for injection COVID-19 mRNA Vaccine (nucleoside \nmodified)” the following entries: \n\n“ \n\nMedicinal \nproduct \n\nDosage and \nconditions of \nadministration \n\nPlace of \nadministr\nation \n\nForm \nand \npresenta\ntion of \nthe \nproduct \nadminist\nered \n\nRoute of \nadministr\nation \n\nIndication \nfor which \nthe \nmedicinal \nproduct \nmay be \nadminister\ned \n\nColumn 1 Column 2 Column 3 Column 4 \n\nColumn 5 \n\nColumn 6 \n\nComirnaty 30 \nmicrograms/d\nose \ndispersion for \n\nReady to \nuse \ndispersio\nn for \ninjection \n\nIntramusc\nular \ninjection \n\nIndicated \nfor active \nimmunisa\ntion to \nprevent \n\nIn accordance \nwith relevant \nrecommendations \nor guidelines \nissued by the \n\nAny \nsuitable and \nappropriate \nplace, \nhaving \n\nNotice of the making of this Statutory Instrument was published in \n“Iris Oifigiúil” of 23rd September, 2022. \n\n \n \n \n \n \n \n \n \n \n\fRoute of \nadministr\nation \n\nIndication \nfor which \nthe \nmedicinal \nproduct \nmay be \nadminister\ned \n\nCOVID19 \n\ncaused by \nSARSCoV-2 \nvirus, in \nindividual\ns 12 years \nof age \nand older \n\nMedicinal \nproduct \n\ninjection \n\nCOVID-19 \nmRNA \nVaccine \n(nucleoside \nmodified) \n\nForm \nand \npresenta\ntion of \nthe \nproduct \nadminist\nered \n\nin a \nmultidos\ne vial \n\nOne dose \n(0.3 mL) \ncontains \n30 \n\nmicrogra\nms of \nCOVID19 \nmRNA \nVaccine. \n\n[467] 3 \n\nDosage and \nconditions of \nadministration \n\nPlace of \nadministr\nation \n\nregard to \npublic \nconvenience \nand the \nneed to \nprotect the \nhealth and \nsafety of the \npublic and \nsafely \nadminister \nthe product \n\nNational \nImmunisation \nAdvisory \nCommittee and \naccepted by the \nMinister for \nHealth. \n\nNotwithstanding \nany directions to \nthe contrary in the \nsummary of \nproduct \ncharacteristics— \n\nan \n\n(a) \nadditional dose \nmay be \nadministered to \nimmunocompromi\nsed persons who \nare 12 years of \nage or older and \nhave already \nreceived a primary \nvaccine course \nagainst Covid-19, \nand \n\na booster \n\n(b) \ndose may be \nadministered to— \n\n(i) \npersons \nwho are 12 years \nof age or older \nand have already \nreceived a primary \nvaccine course \nagainst Covid-19, \nand \n\n \n \n \n \n \n\f4 [467] \n\nMedicinal \nproduct \n\nDosage and \nconditions of \nadministration \n\nPlace of \nadministr\nation \n\nForm \nand \npresenta\ntion of \nthe \nproduct \nadminist\nered \n\nRoute of \nadministr\nation \n\nIndication \nfor which \nthe \nmedicinal \nproduct \nmay be \nadminister\ned \n\n(ii)\n\nimmunoc\n\nompromised \npersons who are \n12 years of age or \nolder and have \nalready received \nan additional dose \nof a Covid-19 \nvaccine, \n\nin such volumes, \nat such intervals, \nin such manner \nand in such order \nof prioritisation \n(whether by \nreference to age, \nemployment \nsector, pregnancy, \nliving \narrangements or \notherwise), as \nmay be specified \nin such \nrecommendations \nor guidelines, and \nsubject to \ninformed consent \nbeing obtained \n\nIn accordance \nwith relevant \nrecommendations \nor guidelines \nissued by the \nNational \nImmunisation \nAdvisory \nCommittee and \naccepted by the \nMinister for \nHealth. \n\nAny \nsuitable \nand \nappropriat\ne place, \nhaving \nregard to \npublic \nconvenien\nce and the \nneed to \nprotect the \nhealth and \nsafety of \n\nIntramusc\nular \ninjection \n\nDispers\nion for \ninjectio\nn in a \nmultido\nse vial \n\nComirnaty \nOriginal/O\nmicron \nBA.1 \n(15/15 \nmicrogram\ns)/dose \ndispersion \nfor \ninjection \n\nCOVID-19 \nmRNA \nVaccine \n\nActive \nimmunis\nation to \nprevent \nCOVID19 \ncaused \nby \nSARSCoV-2, \nin \nindividu\nals 12 \nyears of \n\n \n \n \n \n\fRoute of \nadministr\nation \n\nForm \nand \npresenta\ntion of \nthe \nproduct \nadminist\nered \n\nMedicinal \nproduct \n\n(nucleoside \nmodified) \n\nIndication \nfor which \nthe \nmedicinal \nproduct \nmay be \nadminister\ned \n\nage and \n\nolder \nwho \nhave \nprevious\nly \nreceived \nat least a \nprimary \nvaccinati\non \ncourse \nagainst \nCOVID19 \n\n[467] 5 \n\nDosage and \nconditions of \nadministration \n\nPlace of \nadministr\nation \n\nthe public \nand safely \nadminister \nthe \nproduct. \n\nThe product is to \nbe given to \neligible \nindividuals who \nare 12 years of \nage or older and \nhave previously \nreceived at least \na primary \nvaccination \ncourse against \nCOVID-19. \n\nThe product is to \nbe administered \nin such volumes, \nat such intervals, \nin such manner \nand in such order \nof prioritisation \n(whether by \nreference to age, \nemployment \nsector, \npregnancy, living \narrangements or \notherwise), as \nmay be specified \nin such \nrecommendations \nor guidelines \nwith an interval \nof not less than 4 \nmonths , or 3 \nmonths in \nexceptional \ncircumstances, \nbetween \nadministration of \nthe product and \nthe last prior \ndose of a \nCOVID-19 \nvaccine, or \nconfirmed \n\n \n \n \n\fForm \nand \npresenta\ntion of \nthe \nproduct \nadminist\nered \n\nDispers\nion for \ninjectio\nn in a \nmultido\nse vial \n\n6 [467] \n\nMedicinal \nproduct \n\nComirnaty \nOriginal/O\nmicron \nBA.4-5 \n(15/15 \nmicrogram\ns)/dose \ndispersion \nfor \ninjection \n\nCOVID-19 \nmRNA \nVaccine \n(nucleoside \nmodified) \n\nDosage and \nconditions of \nadministration \n\nPlace of \nadministr\nation \n\nRoute of \nadministr\nation \n\nIndication \nfor which \nthe \nmedicinal \nproduct \nmay be \nadminister\ned \n\nIntramusc\nular \ninjection \n\nAny \nsuitable \nand \nappropriat\ne place, \nhaving \nregard to \npublic \nconvenien\nce and the \nneed to \nprotect the \nhealth and \nsafety of \nthe public \nand safely \nadminister \nthe \nproduct. \n\nActive \nimmunis\nation to \nprevent \nCOVID19 \ncaused \nby \nSARSCoV-2, \nin \nindividu\nals 12 \nyears of \nage and \n\nolder \nwho \nhave \nprevious\nly \nreceived \nat least a \nprimary \nvaccinati\non \ncourse \nagainst \nCOVID19 \n\nSARS-CoV-2 \ninfection. \n\nIn accordance \nwith relevant \nrecommendations \nor guidelines \nissued by the \nNational \nImmunisation \nAdvisory \nCommittee and \naccepted by the \nMinister for \nHealth \n\nThe product is to \nbe given to \neligible \nindividuals who \nare 12 years of \nage or older and \nhave previously \nreceived at least \na primary \nvaccination \ncourse against \nCOVID-19. \n\nThe product is to \nbe administered \nin such volumes, \nat such intervals, \nin such manner \nand in such order \nof prioritisation \n(whether by \nreference to age, \nemployment \nsector, \npregnancy, living \narrangements or \notherwise), as \nmay be specified \n\n \n \n \n \n \n\f[467] 7 \n\nDosage and \nconditions of \nadministration \n\nPlace of \nadministr\nation \n\nMedicinal \nproduct \n\nForm \nand \npresenta\ntion of \nthe \nproduct \nadminist\nered \n\nRoute of \nadministr\nation \n\nIndication \nfor which \nthe \nmedicinal \nproduct \nmay be \nadminister\ned \n\nin such \nrecommendations \nor guidelines \nwith an interval \nof not less than 4 \nmonths, or 3 \nmonths in \nexceptional \ncircumstances, \nbetween \nadministration of \nthe product and \nthe last prior \ndose of a \nCOVID-19 \nvaccine, or \nconfirmed \nSARS-CoV-2 \ninfection. \n\n”, and \n\n(b) by inserting after the entry for “Spikevax (previously Covid-19 \nVaccine Moderna) dispersion for injection COVID-19 mRNA \nVaccine (nucleoside modified)” the following entry: \n\n“ \n\nMedicinal \nproduct \n\nRoute of \nadministr\nation \n\nForm \nand \npresenta\ntion of \nthe \nproduct \nadminist\nered \n\nColumn 1 \n\nColumn 2 Column 3 \n\nIndicatio\nn for \nwhich \nthe \nmedicina\nl product \nmay be \nadminist\nered \nColumn 4 \n\nDosage and \nconditions \nof \nadministrat\nion \n\nPlace of \nadministra\ntion \n\nColumn 5 \n\nColumn 6 \n\nIntramuscu\nlar \ninjection. \n\nSpikevax \nbivalent \nOriginal/Om\nicron BA.1 \n(50 \nmicrograms/\n50 \n\nDispersio\nn for \ninjection \nin a \nmultidose \nvial \n\nActive \nimmunisa\ntion to \nprevent \nCOVID19 caused \nby \n\nIn accordance \nwith relevant \nrecommendati\nons or \nguidelines \nissued by the \nNational \n\nAny \nsuitable \nand \nappropriate \nplace, \nhaving \nregard to \n\n \n \n \n\f8 [467] \n\nmicrograms)\n/mL \ndispersion \nfor \n\ninjection \n\nCOVID-19 \nmRNA \nVaccine \n(nucleoside \nmodified) \n\npublic \nconvenienc\ne and the \nneed to \nprotect the \nhealth and \nsafety of \nthe public \nand safely \nadminister \nthe product \n\nSARSCoV-2 in \nindividua\nls 30 \nyears of \nage and \nolder who \nhave \npreviousl\ny \nreceived \nat least a \nprimary \nvaccinati\non course \nagainst \nCOVID19 \n\nImmunisation \nAdvisory \nCommittee \nand accepted \nby the \nMinister for \nHealth. \n\nNotwithstan\nding any \ndirections to \nthe contrary \nin the \nsummary of \nproduct \ncharacteristi\ncs, the \nproduct \nshall only be \nadministered \nto eligible \nindividuals \nwho are 30 \nyears of age \nor older and \nhave \npreviously \nreceived at \nleast a \nprimary \nvaccination \ncourse \nagainst \nCOVID-19. \n\nThe product \nis to be \nadministered \nin such \nvolumes, at \nsuch \nintervals, in \nsuch manner \nand in such \norder of \nprioritisation \n(whether by \nreference to \nage, \nemployment \nsector, \npregnancy, \nliving \n\n \n \n \n \n\f[467] 9 \n\narrangement\ns or \notherwise), \nas may be \nspecified in \nsuch \nrecommenda\ntions or \nguidelines \nwith an \ninterval of \nnot less than \n4 months, or \n3 months in \nexceptional \ncircumstanc\nes, between \nadministrati\non of the \nproduct and \nthe last prior \ndose of a \nCOVID-19 \nvaccine, or \nconfirmed \nSARS-CoV2 infection. \n\n”.", "text_norm": "3 eighth schedule (as amended regulation 3 regulation 2022) principal regulation amended-- (a) inserting entry comirnaty concentrate dispersion injection covid-19 mrna vaccine (nucleoside modified) following entry medicinal product dosage condition administration place administr ation form presenta tion product administ ered route administr ation indication medicinal product may administer ed column 1 column 2 column 3 column 4 column 5 column 6 comirnaty 30 microgram ose dispersion ready use dispersio n injection intramusc ular injection indicated active immunisa tion prevent accordance relevant recommendation guideline issued suitable appropriate place notice making statutory instrument published iris oifigiuil 23rd september 2022 route administr ation indication medicinal product may administer ed covid19 caused sarscov-2 virus individual 12 year age older medicinal product injection covid-19 mrna vaccine (nucleoside modified) form presenta tion product administ ered multidos e vial one dose (0.3 ml) contains 30 microgra m covid19 mrna vaccine 467 3 dosage condition administration place administr ation regard public convenience need protect health safety public safely administer product national immunisation advisory committee accepted minister health notwithstanding direction contrary summary product characteristics-- (a) additional dose may administered immunocompromi sed person 12 year age older already received primary vaccine course covid-19 booster (b) dose may administered to-- (i) person 12 year age older already received primary vaccine course covid-19 4 467 medicinal product dosage condition administration place administr ation form presenta tion product administ ered route administr ation indication medicinal product may administer ed (ii) immunoc ompromised person 12 year age older already received additional dose covid-19 vaccine volume interval manner order prioritisation (whether reference age employment sector pregnancy living arrangement otherwise) may specified recommendation guideline subject informed consent obtained accordance relevant recommendation guideline issued national immunisation advisory committee accepted minister health suitable appropriat e place regard public convenien ce need protect health safety intramusc ular injection dispers ion injectio n multido se vial comirnaty original micron ba.1 (15 15 microgram s) dose dispersion injection covid-19 mrna vaccine active immunis ation prevent covid19 caused sarscov-2 individu al 12 year route administr ation form presenta tion product administ ered medicinal product (nucleoside modified) indication medicinal product may administer ed age older previous ly received least primary vaccinati course covid19 467 5 dosage condition administration place administr ation public safely administer product product given eligible individual 12 year age older previously received least primary vaccination course covid-19 product administered volume interval manner order prioritisation (whether reference age employment sector pregnancy living arrangement otherwise) may specified recommendation guideline interval le 4 month 3 month exceptional circumstance administration product last prior dose covid-19 vaccine confirmed form presenta tion product administ ered dispers ion injectio n multido se vial 6 467 medicinal product comirnaty original micron ba.4-5 (15 15 microgram s) dose dispersion injection covid-19 mrna vaccine (nucleoside modified) dosage condition administration place administr ation route administr ation indication medicinal product may administer ed intramusc ular injection suitable appropriat e place regard public convenien ce need protect health safety public safely administer product active immunis ation prevent covid19 caused sarscov-2 individu al 12 year age older previous ly received least primary vaccinati course covid19 sars-cov-2 infection accordance relevant recommendation guideline issued national immunisation advisory committee accepted minister health product given eligible individual 12 year age older previously received least primary vaccination course covid-19 product administered volume interval manner order prioritisation (whether reference age employment sector pregnancy living arrangement otherwise) may specified 467 7 dosage condition administration place administr ation medicinal product form presenta tion product administ ered route administr ation indication medicinal product may administer ed recommendation guideline interval le 4 month 3 month exceptional circumstance administration product last prior dose covid-19 vaccine confirmed sars-cov-2 infection (b) inserting entry spikevax (previously covid-19 vaccine moderna) dispersion injection covid-19 mrna vaccine (nucleoside modified) following entry medicinal product route administr ation form presenta tion product administ ered column 1 column 2 column 3 indicatio n medicina l product may administ ered column 4 dosage condition administrat ion place administra tion column 5 column 6 intramuscu lar injection spikevax bivalent original om icron ba.1 (50 microgram 50 dispersio n injection multidose vial active immunisa tion prevent covid19 caused accordance relevant recommendati ons guideline issued national suitable appropriate place regard 8 467 micrograms) ml dispersion injection covid-19 mrna vaccine (nucleoside modified) public convenienc e need protect health safety public safely administer product sarscov-2 individua l 30 year age older previousl received least primary vaccinati course covid19 immunisation advisory committee accepted minister health notwithstan ding direction contrary summary product characteristi c product shall administered eligible individual 30 year age older previously received least primary vaccination course covid-19 product administered volume interval manner order prioritisation (whether reference age employment sector pregnancy living 467 9 arrangement otherwise) may specified recommenda tions guideline interval le 4 month 3 month exceptional circumstanc e administrati product last prior dose covid-19 vaccine confirmed sars-cov2 infection", "start_char": 1227, "end_char": 10160, "source_path": "downloads\\2022\\2022_0466.pdf", "extraction_method": "pdfminer", "checksum": "sha256:6019fd6b368a8c147a0a394bd4c11b96f3897bb771ba4d88d743e1d9a857e78f", "cross_refs": []}
{"doc_id": "si-2022-0467-reg-4", "parent_doc_id": "si-2022-0467", "section_id": "reg-4", "section_label": "Regulation 4.", "si_number": "S.I. No. 467 of 2022", "title": "and Control of Supply) Regulations 2003 to 2022” includes these Regulations.", "year": 2022, "heading": "4. The Twelfth Schedule (as amended by Regulation 4 of the Regulations", "text_raw": "4. The Twelfth Schedule (as amended by Regulation 4 of the Regulations \n\nof 2022) to the Principal Regulations is amended— \n\n(a) by inserting after the entry for “Comirnaty concentrate for \ndispersion for injection COVID-19 mRNA Vaccine (nucleoside \nmodified)” the following entries: \n\n“ \n\nMedicinal \nproduct \n\nRoute of \nadministra\ntion \n\nForm \nand \npresentat\nion of the \nproduct \nadministe\nred \n\nIndication \nfor which \nthe \nmedicinal \nproduct \nmay be \nadministe\nred \n\nDosage and conditions of \nadministration \n\nColumn 1 \n\nColumn 2 Column 3 Column 4 \n\nColumn 5 \n\nComirnaty 30 \nmicrograms/do\nse dispersion \nfor injection \n\nCOVID-19 \nmRNA \n\nReady for \nuse \ndispersion \nfor \ninjection \nin a \nmultidose \n\nIntramuscul\nar Injection \n\nIndicated \nfor active \nimmunisati\non to \nprevent \nCOVID-19 \n\nIn accordance with \nrelevant recommendations \nor guidelines issued by the \nNational Immunisation \nAdvisory Committee and \naccepted by the Minister \n\n \n \n\f10 [467] \n\nMedicinal \nproduct \n\nVaccine \n(nucleoside \nmodified) \n\nRoute of \nadministra\ntion \n\nIndication \nfor which \nthe \nmedicinal \nproduct \nmay be \nadministe\nred \n\ncaused by \nSARSCoV-2 \nvirus, in \nindividuals \n12 years of \nage and \nolder \n\nForm \nand \npresentat\nion of the \nproduct \nadministe\nred \n\nvial \n\nOne dose \n(0.3 mL) \ncontains \n30 \n\nmicrogra\nms of \nCOVID19 mRNA \nVaccine. \n\nDosage and conditions of \nadministration \n\nfor Health. \n\nNotwithstanding any \ndirections to the contrary \nin the summary of product \ncharacteristics— \n\n(a) an additional dose \n\nmay be administered \nto \nimmunocompromise\nd persons who are 12 \nyears of age or older \nand have already \nreceived a primary \nvaccine course \nagainst Covid-19, \nand \n\n(b) a booster dose may \n\nbe administered to— \n\n(i) persons who are \n\n12 years of age or \nolder and have \nalready received a \nprimary vaccine \ncourse against \nCovid-19, and \n\n(ii) immunocomprom\nised persons who \nare 12 years of \nage or older and \nhave already \nreceived an \nadditional dose of \na Covid-19 \nvaccine, \n\n \n \n \n \n \n \n \n\fMedicinal \nproduct \n\nRoute of \nadministra\ntion \n\nForm \nand \npresentat\nion of the \nproduct \nadministe\nred \n\nIndication \nfor which \nthe \nmedicinal \nproduct \nmay be \nadministe\nred \n\nIntramuscul\nar injection \n\nDispersi\non for \ninjection \nin a \nmultidos\ne vial \n\nComirnaty \nOriginal/Om\nicron BA.1 \n(15/15 \nmicrograms)\n/dose \ndispersion \nfor injection \n\nCOVID-19 \nmRNA \nVaccine \n(nucleoside \nmodified) \n\nActive \nimmunisa\ntion to \nprevent \nCOVID19 caused \nby \nSARSCoV-2, in \nindividua\nls 12 \nyears of \nage and \n\nolder who \nhave \npreviousl\ny \nreceived \nat least a \nprimary \nvaccinati\non course \nagainst \nCOVID19 \n\n[467] 11 \n\nDosage and conditions of \nadministration \n\nin such volumes, at such \nintervals, in such manner \nand in such order of \nprioritisation (whether by \nreference to age, \nemployment sector, \npregnancy, living \narrangements or otherwise), \nas may be specified in such \nrecommendations or \nguidelines, and subject to \ninformed consent being \nobtained. \n\nIn accordance with \nrelevant recommendations \nor guidelines issued by the \nNational Immunisation \nAdvisory Committee and \naccepted by the Minister \nfor Health \n\nThe product is to be given \n(as a booster dose) to \neligible individuals who \nare 12 years of age or \nolder and have previously \nreceived at least a primary \nvaccination course against \nCOVID-19. \n\nThe product is to be \nadministered in such \nvolumes, at such intervals, \nin such manner and in \nsuch order of eligibility \nand prioritisation (whether \nby reference to age, \nemployment sector, \npregnancy, living \narrangements or \notherwise), as may be \n\n \n \n \n \n\f12 [467] \n\nMedicinal \nproduct \n\nDosage and conditions of \nadministration \n\nRoute of \nadministra\ntion \n\nForm \nand \npresentat\nion of the \nproduct \nadministe\nred \n\nIndication \nfor which \nthe \nmedicinal \nproduct \nmay be \nadministe\nred \n\nIntramuscul\nar injection \n\nDispersi\non for \ninjection \nin a \nmultidos\ne vial \n\nComirnaty \nOriginal/Om\nicron BA.45 \n(15/15 \nmicrograms)\n/dose \ndispersion \nfor injection \n\nCOVID-19 \nmRNA \nVaccine \n(nucleoside \nmodified) \n\nspecified in such \nrecommendations or \nguidelines with an interval \nof not less than 4 months, \nor 3 months in exceptional \ncircumstances between \nadministration of the \nproduct and the last prior \ndose of a COVID-19 \nvaccine, or confirmed \nSARS-CoV-2 infection. \n\nIn accordance with \nrelevant recommendations \nor guidelines issued by the \nNational Immunisation \nAdvisory Committee and \naccepted by the Minister \nfor Health \n\nThe product is to be given \nto eligible individuals who \nare 12 years of age or \nolder and have previously \nreceived at least a primary \nvaccination course against \nCOVID-19. \n\nThe product is to be \nadministered in such \nvolumes, at such intervals, \nin such manner and in \nsuch order of prioritisation \n(whether by reference to \nage, employment sector, \npregnancy, living \narrangements or \notherwise), as may be \nspecified in such \nrecommendations or \nguidelines with an interval \nof not less than 4 months \nor 3 months in exceptional \n\nActive \nimmunisa\ntion to \nprevent \nCOVID19 caused \nby \nSARSCoV-2, in \nindividua\nls 12 \nyears of \nage and \n\nolder who \nhave \npreviousl\ny \nreceived \nat least a \nprimary \nvaccinati\non course \nagainst \nCOVID19 \n\n \n \n \n\fMedicinal \nproduct \n\nRoute of \nadministra\ntion \n\nForm \nand \npresentat\nion of the \nproduct \nadministe\nred \n\nIndication \nfor which \nthe \nmedicinal \nproduct \nmay be \nadministe\nred \n\n[467] 13 \n\nDosage and conditions of \nadministration \n\ncircumstances, between \nadministration of the \nproduct and the last prior \ndose of a COVID-19 \nvaccine, or confirmed \nSARS-CoV-2 infection. \n\n”, and \n\n(b) by inserting after the entry for “Spikevax (previously Covid-19 \nVaccine Moderna) dispersion for injection COVID-19 mRNA \nVaccine (nucleoside modified)” the following entry: \n\n“ \n\nMedicinal \nproduct \n\nRoute of \nadministration \n\nForm and \npresentation \nof the \nproduct \nadministered \n\nColumn 1 \n\nColumn 2 \n\nColumn 3 \n\nIntramuscula\nr injection \n\nDispersio\nn for \ninjection \nin a \nmultidose \nvial \n\nSpikevax \nbivalent \nOriginal/Omicro\nn BA.1 (50 \nmicrograms/50 \nmicrograms)/mL \ndispersion for \n\ninjection \n\nCOVID-19 \nmRNA Vaccine \n(nucleoside \nmodified) \n\nIndication \nfor which the \nmedicinal \nproduct may \nbe \nadministered \nColumn 4 \n\nActive \nimmunisatio\nn to prevent \nCOVID-19 \n\ncaused by \nSARS-CoV2 in \nindividuals \n30 years of \nage and \nolder who \nhave \npreviously \nreceived at \nleast \n\na primary \nvaccination \ncourse \nagainst \nCOVID-19 \n\nDosage and \nconditions of \nadministration \n\nColumn 5 \n\nIn accordance \nwith relevant \nrecommendation\ns or guidelines \nissued by the \nNational \nImmunisation \nAdvisory \nCommittee and \naccepted by the \nMinister for \nHealth. \n\nNotwithstanding \nany directions to \nthe contrary in \nthe summary of \nproduct \ncharacteristics, \nthe product shall \nonly be \n\n \n \n \n \n\f14 [467] \n\n”. \n\nadministered to \neligible \nindividuals who \nare 30 years of \nage or older and \nhave previously \nreceived at least \na primary \nvaccination \ncourse against \nCOVID-19. \n\nThe product is \nto be \nadministered in \nsuch volumes, at \nsuch intervals, \nin such manner \nand in such \norder of \nprioritisation \n(whether by \nreference to age, \nemployment \nsector, \npregnancy, \nliving \narrangements or \notherwise), as \nmay be \nspecified in such \nrecommendation\ns or guidelines \nwith an interval \nof not less than \n4 months , or 3 \nmonths in \nexceptional \ncircumstances, \nbetween \nadministration \nof the product \nand the last prior \ndose of a \nCOVID-19 \nvaccine, or \nconfirmed \nSARS-CoV-2 \ninfection. \n\n \n \n \n\f[467] 15 \n\nGIVEN under my Official Seal, \n\n20 September, 2022. \n\nSTEPHEN DONNELLY, \nMinister for Health. \n\n \n \n \n \n \n \n\f16 [467]", "text_norm": "4 twelfth schedule (as amended regulation 4 regulation 2022) principal regulation amended-- (a) inserting entry comirnaty concentrate dispersion injection covid-19 mrna vaccine (nucleoside modified) following entry medicinal product route administra tion form presentat ion product administe red indication medicinal product may administe red dosage condition administration column 1 column 2 column 3 column 4 column 5 comirnaty 30 microgram se dispersion injection covid-19 mrna ready use dispersion injection multidose intramuscul ar injection indicated active immunisati prevent covid-19 accordance relevant recommendation guideline issued national immunisation advisory committee accepted minister 10 467 medicinal product vaccine (nucleoside modified) route administra tion indication medicinal product may administe red caused sarscov-2 virus individual 12 year age older form presentat ion product administe red vial one dose (0.3 ml) contains 30 microgra m covid19 mrna vaccine dosage condition administration health notwithstanding direction contrary summary product characteristics-- (a) additional dose may administered immunocompromise person 12 year age older already received primary vaccine course covid-19 (b) booster dose may administered to-- (i) person 12 year age older already received primary vaccine course covid-19 (ii) immunocomprom ised person 12 year age older already received additional dose covid-19 vaccine medicinal product route administra tion form presentat ion product administe red indication medicinal product may administe red intramuscul ar injection dispersi injection multidos e vial comirnaty original om icron ba.1 (15 15 micrograms) dose dispersion injection covid-19 mrna vaccine (nucleoside modified) active immunisa tion prevent covid19 caused sarscov-2 individua l 12 year age older previousl received least primary vaccinati course covid19 467 11 dosage condition administration volume interval manner order prioritisation (whether reference age employment sector pregnancy living arrangement otherwise) may specified recommendation guideline subject informed consent obtained accordance relevant recommendation guideline issued national immunisation advisory committee accepted minister health product given (as booster dose) eligible individual 12 year age older previously received least primary vaccination course covid-19 product administered volume interval manner order eligibility prioritisation (whether reference age employment sector pregnancy living arrangement otherwise) may 12 467 medicinal product dosage condition administration route administra tion form presentat ion product administe red indication medicinal product may administe red intramuscul ar injection dispersi injection multidos e vial comirnaty original om icron ba.45 (15 15 micrograms) dose dispersion injection covid-19 mrna vaccine (nucleoside modified) specified recommendation guideline interval le 4 month 3 month exceptional circumstance administration product last prior dose covid-19 vaccine confirmed sars-cov-2 infection accordance relevant recommendation guideline issued national immunisation advisory committee accepted minister health product given eligible individual 12 year age older previously received least primary vaccination course covid-19 product administered volume interval manner order prioritisation (whether reference age employment sector pregnancy living arrangement otherwise) may specified recommendation guideline interval le 4 month 3 month exceptional active immunisa tion prevent covid19 caused sarscov-2 individua l 12 year age older previousl received least primary vaccinati course covid19 medicinal product route administra tion form presentat ion product administe red indication medicinal product may administe red 467 13 dosage condition administration circumstance administration product last prior dose covid-19 vaccine confirmed sars-cov-2 infection (b) inserting entry spikevax (previously covid-19 vaccine moderna) dispersion injection covid-19 mrna vaccine (nucleoside modified) following entry medicinal product route administration form presentation product administered column 1 column 2 column 3 intramuscula r injection dispersio n injection multidose vial spikevax bivalent original omicro n ba.1 (50 microgram 50 micrograms) ml dispersion injection covid-19 mrna vaccine (nucleoside modified) indication medicinal product may administered column 4 active immunisatio n prevent covid-19 caused sars-cov2 individual 30 year age older previously received least primary vaccination course covid-19 dosage condition administration column 5 accordance relevant recommendation guideline issued national immunisation advisory committee accepted minister health notwithstanding direction contrary summary product characteristic product shall 14 467  administered eligible individual 30 year age older previously received least primary vaccination course covid-19 product administered volume interval manner order prioritisation (whether reference age employment sector pregnancy living arrangement otherwise) may specified recommendation guideline interval le 4 month 3 month exceptional circumstance administration product last prior dose covid-19 vaccine confirmed sars-cov-2 infection 467 15 given official seal 20 september 2022 stephen donnelly minister health 16 467", "start_char": 10160, "end_char": 17800, "source_path": "downloads\\2022\\2022_0466.pdf", "extraction_method": "pdfminer", "checksum": "sha256:6019fd6b368a8c147a0a394bd4c11b96f3897bb771ba4d88d743e1d9a857e78f", "cross_refs": []}
{"doc_id": "si-2022-0467-explanatory-note", "parent_doc_id": "si-2022-0467", "section_id": "explanatory-note", "section_label": "EXPLANATORY NOTE", "si_number": "S.I. No. 467 of 2022", "title": "and Control of Supply) Regulations 2003 to 2022” includes these Regulations.", "year": 2022, "heading": "(This note is not part of the Instrument and does not purport to be a legal", "text_raw": "EXPLANATORY NOTE \n\n(This note is not part of the Instrument and does not purport to be a legal \ninterpretation.) \n\nThese Regulations amend the Medicinal Products (Prescription and Control of \nSupply) Regulations 2003. \n\nThe purpose of these Regulations is to amend the relevant schedules in relation \nto the COVID-19 vaccines to provide for the administration of bivalent adapted \nCovid vaccines as booster doses, and to add an additional product formulation \nof the original Comirnaty product. \n\nThese Regulations may be cited as the Medicinal Products (Prescription and \nControl of Supply) (Amendment) (No. 5) Regulations 2022. \n\n \n \n \n \n \n \n \n \n \n\f[467] 17 \n\nBAILE ÁTHA CLIATH \nARNA FHOILSIÚ AG OIFIG AN tSOLÁTHAIR \nLe ceannach díreach ó \nFOILSEACHÁIN RIALTAIS, \nBÓTHAR BHAILE UÍ BHEOLÁIN, \nCILL MHAIGHNEANN, \nBAILE ÁTHA CLIATH 8, \nD08 XAO6 \n\nTeil: 046 942 3100 \nr-phost: publications@opw.ie \n—————— \n\nDUBLIN \nPUBLISHED BY THE STATIONERY OFFICE \nTo be purchased from \nGOVERNMENT PUBLICATIONS, \nMOUNTSHANNON ROAD, \nKILMAINHAM, DUBLIN 8, \nD08 XAO6 \n\nTel: 046 942 3100 \nE-mail: publications@opw.ie \n—————— \n\n€ 4.50 \n\n(DH-444) 75. 9/22. Propylon.", "text_norm": "explanatory note (this note part instrument purport legal interpretation.) regulation amend medicinal product (prescription control supply) regulation 2003 purpose regulation amend relevant schedule relation covid-19 vaccine provide administration bivalent adapted covid vaccine booster dos add additional product formulation original comirnaty product regulation may cited medicinal product (prescription control supply) (amendment) (no 5) regulation 2022 467 17 baile atha cliath arna fhoilsiu ag oifig tsolathair le ceannach direach foilseachain rialtais bothar bhaile ui bheolain cill mhaighneann baile atha cliath 8 d08 xao6 teil 046 942 3100 r-phost publication opw.ie ------------ dublin published stationery office purchased government publication mountshannon road kilmainham dublin 8 d08 xao6 tel 046 942 3100 e-mail publication opw.ie ------------ eur 4.50 (dh-444) 75 9 22 propylon", "start_char": 17800, "end_char": 18945, "source_path": "downloads\\2022\\2022_0466.pdf", "extraction_method": "pdfminer", "checksum": "sha256:6019fd6b368a8c147a0a394bd4c11b96f3897bb771ba4d88d743e1d9a857e78f", "cross_refs": []}
